Cardiol Therapeutics Inc.(CRDL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.1M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CRDL Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Cardiol Therapeutics Inc. (CRDL), a Healthcare sector company. CRDL is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.1m in revenue and is scored on the micro-cap board instead. Top institutional holders of CRDL by reported 13-F value include MMCAP International SPC, Tejara Capital Ltd, Ikarian Capital, based on the most recent SEC filings. CRDL trades on the Nasdaq exchange and files with the SEC under CIK 1702123. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRDL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cardiol Therapeutics Inc. directly from SEC EDGAR.
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Total Assets
-13.2% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $78.8K | — | — |
| Total Assets | $31.9M -13.2% | $36.7M -40.8% | $62.0M -29.4% | $87.9M +452.9% | $15.9M | — |
Get alerted when CRDL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Cardiol Therapeutics Inc. including:
Top Institutional Holders of CRDL
MMCAP International Inc. SPC
$16.5M15,598,560 shTejara Capital Ltd
$5.4M5,113,822 shIkarian Capital, LLC
$3.5M3,325,000 shBOOTHBAY FUND MANAGEMENT, LLC
$1.0M975,721 shCITADEL ADVISORS LLC
$844.3K796,529 shRENAISSANCE TECHNOLOGIES LLC
$819.2K772,837 shTWO SIGMA INVESTMENTS, LP
$791.8K746,937 shINTEGRITY ALLIANCE, LLC.
$411.8K388,492 shMORGAN STANLEY
$376.3K355,030 shGOLDMAN SACHS GROUP INC
$353.9K333,900 sh
| Fund | Value | Shares |
|---|---|---|
| MMCAP International Inc. SPC | $16.5M | 15,598,560 |
| Tejara Capital Ltd | $5.4M | 5,113,822 |
| Ikarian Capital, LLC | $3.5M | 3,325,000 |
| BOOTHBAY FUND MANAGEMENT, LLC | $1.0M | 975,721 |
| CITADEL ADVISORS LLC | $844.3K | 796,529 |
| RENAISSANCE TECHNOLOGIES LLC | $819.2K | 772,837 |
| TWO SIGMA INVESTMENTS, LP | $791.8K | 746,937 |
| INTEGRITY ALLIANCE, LLC. | $411.8K | 388,492 |
| MORGAN STANLEY | $376.3K | 355,030 |
| GOLDMAN SACHS GROUP INC | $353.9K | 333,900 |
More Healthcare Companies
View all Healthcare →Put CRDL on your watchlist
Track score changes the day Cardiol Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CRDL a good stock to buy?
13F Pro's AI-powered analysis of Cardiol Therapeutics Inc. (CRDL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRDL are available on the CRDL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CRDL is classified as a small company.
Which hedge funds own CRDL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRDL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cardiol Therapeutics Inc.'s investment landscape.